Manager Network and Events, Healthcare Innovation - DayOne
Tel. +41 61 295 50 16thomas. brenzikofer@baselarea. swiss
Pharmaceutical company Merck is using the Genedata Biologics platform developed by Genedata to scale-up their bispecific antibody research. The aim is to develop innovative therapeutics for oncology, immunology and neurodegenerative diseases.
The Basel-based company Genedata develops software for scientific applications. One of these is the Genedata Biologics system, which can be used to research bispecific antibodies that are able to identify two different antigens.
According to a press release, Genedata first released this platform in 2011. Merck began using it in 2015 and has since expanded application to encompass ever more areas. The pharma company is now planning to scale-up its bispecific discovery programmes with Genedata Biologics. This research area involves the need to evaluate large panels of bispecific antibodies. Genedata’s software substantially enhances throughput volumes. Merck uses this research to develop therapeutics for oncology, immunology and neurodegenerative diseases.
“We are delighted to see Merck expand the application scope of Genedata Biologics to their innovative bispecific research and development programmes,” commented Dr Othmar Pfannes, CEO of Genedata. He also said that the company intends to further expand the platform in close collaboration with its growing customer base to support new technologies, which will include cell and gene therapies.